BioInvent International AB (publ)
BioInvent International AB (publ), a clinical-stage company, discovers and develops immuno-modulatory antibodies for the treatment of cancer in Sweden, Europe, the United States, and internationally. The company's drug candidates include BI-1808, an anti- tumor necrosis factor receptor-2 (TNFR2) antibody in Phase 2a trial for the treatment of solid tumors and a type of blood cancer; BI-1206, an a… Read more
BioInvent International AB (publ) - Asset Resilience Ratio
BioInvent International AB (publ) (BOVNF) has an Asset Resilience Ratio of 26.36% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2005–2024)
This chart shows how BioInvent International AB (publ)'s Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down BioInvent International AB (publ)'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $205.75 Million | 26.36% |
| Total Liquid Assets | $205.75 Million | 26.36% |
Asset Resilience Insights
- Very High Liquidity: BioInvent International AB (publ) maintains exceptional liquid asset reserves at 26.36% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
BioInvent International AB (publ) Industry Peers by Asset Resilience Ratio
Compare BioInvent International AB (publ)'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
MedPacto Inc
KQ:235980 |
Biotechnology | 49.82% |
|
Shenzhen CAU Technology Co Ltd
SHE:000004 |
Biotechnology | 6.20% |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403 |
Biotechnology | 6.88% |
|
Nanhua Bio Medicine Co Ltd
SHE:000504 |
Biotechnology | 11.93% |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518 |
Biotechnology | 0.03% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
|
Hualan Biological EngineeringInc
SHE:002007 |
Biotechnology | 14.68% |
|
Da An Gene Co Ltd of Sun Yat-Sen University
SHE:002030 |
Biotechnology | 4.35% |
Annual Asset Resilience Ratio for BioInvent International AB (publ) (2005–2024)
The table below shows the annual Asset Resilience Ratio data for BioInvent International AB (publ).
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 43.70% | $432.33 Million | $989.24 Million | -14.09pp |
| 2023-12-31 | 57.79% | $809.15 Million | $1.40 Billion | +28.44pp |
| 2022-12-31 | 29.34% | $502.43 Million | $1.71 Billion | +17.45pp |
| 2021-12-31 | 11.89% | $172.07 Million | $1.45 Billion | -- |
| 2018-12-31 | 0.00% | $0.00 | $120.40 Million | -- |
| 2017-12-31 | 17.68% | $30.06 Million | $170.05 Million | -- |
| 2016-12-31 | 0.00% | $0.00 | $276.30 Million | -- |
| 2015-12-31 | 0.00% | $0.00 | $54.45 Million | -- |
| 2014-12-31 | 49.97% | $37.03 Million | $74.11 Million | -11.52pp |
| 2013-12-31 | 61.49% | $50.07 Million | $81.44 Million | +21.82pp |
| 2011-12-31 | 39.67% | $81.62 Million | $205.76 Million | -10.41pp |
| 2010-12-31 | 50.07% | $69.12 Million | $138.03 Million | +42.17pp |
| 2009-12-31 | 7.91% | $9.98 Million | $126.25 Million | -5.55pp |
| 2006-12-31 | 13.45% | $19.96 Million | $148.33 Million | -8.99pp |
| 2005-12-31 | 22.45% | $59.78 Million | $266.34 Million | -- |